Moderna sees 2027 respiratory product sales $8B-$15B

The Company estimates respiratory product sales in 2027 to be in the range of $8 billion to $15 billion with corresponding Respiratory operating profit in the range of $4 billion to $9 billion. This framework is supported by $6 billion to $8 billion of additional research and development investments over the next few years. Of note, these estimates are for the respiratory vaccine business only and do not include forecasts for other Moderna products or investments.